GlassScriptPhysician profile
Ho Sung Sung Pak
NPI 1518025766
$3,363.39
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $519 · 2021: $1,011 · 2022: $731 · 2023: $686 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.77 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $361.61 | 2019-2023 | Myrbetriq, Veozah |
| Amgen INC. | $280.68 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $278.91 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $276.13 | 2019-2023 | |
| Amarin Pharma, INC. | $252.93 | 2019-2022 | |
| Lilly USA, LLC | $218.36 | 2020-2023 | Jardiance, Mounjaro |
| Medtronic, INC. | $128.68 | 2021-2024 | Linq II |
| Ge Healthcare | $119.25 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $104.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.43 | 2021-2023 | Xifaxan |
| Abbott Laboratories | $94.78 | 2021-2023 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $85.25 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $81.18 | 2022 | |
| Esperion Therapeutics, INC. | $61.61 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $59.05 | 2022 | |
| Mylan Specialty L.P. | $53.36 | 2020-2021 | |
| Abbvie INC. | $45.76 | 2023 | |
| Janssen Pharmaceuticals, INC | $44.94 | 2021 | |
| Genentech USA, INC. | $39.39 | 2020 | |
| Paratek Pharmaceuticals, INC. | $36.31 | 2021 | |
| Mannkind Corporation | $27.08 | 2022-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2022 | |
| Itamar Medical INC | $19.40 | 2023 | Watchpatone |
| Bigfoot Biomedical INC | $16.86 | 2021 | |
| Organon LLC | $16.85 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $16.71 | 2023 | Relyvrio |
| Biohaven Pharmaceuticals, INC. | $13.34 | 2021 | |
| Alfasigma USA, INC. | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ho Sung Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.